| Autor: |
Santos-López G; Laboratorio de Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec 74360, Mexico.; National Network of Viral Hepatitis Researchers, Mexico City, Mexico., Panduro A; National Network of Viral Hepatitis Researchers, Mexico City, Mexico.; Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Health Sciences Center, University of Guadalajara, Guadalajara 44280, Mexico., Sosa-Jurado F; Laboratorio de Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec 74360, Mexico.; National Network of Viral Hepatitis Researchers, Mexico City, Mexico., Fierro NA; National Network of Viral Hepatitis Researchers, Mexico City, Mexico.; Department of Immunology, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico., Lira R; National Network of Viral Hepatitis Researchers, Mexico City, Mexico.; Unidad de Investigación Biomédica Oncológica Genómica, Hospital Gineco Pediatría 3A, OOAD Cd Mx Norte, Instituto Mexicano del Seguro Social, Mexico City 07760, Mexico., Márquez-Domínguez L; Laboratorio de Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec 74360, Mexico.; National Network of Viral Hepatitis Researchers, Mexico City, Mexico., Cerbón M; National Network of Viral Hepatitis Researchers, Mexico City, Mexico.; Facultad de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico., Méndez-Sánchez N; National Network of Viral Hepatitis Researchers, Mexico City, Mexico.; Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico., Roman S; National Network of Viral Hepatitis Researchers, Mexico City, Mexico.; Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Health Sciences Center, University of Guadalajara, Guadalajara 44280, Mexico. |
| Abstrakt: |
Viral hepatitis (A-E) presents a major global health challenge. In 2015, the World Health Organization (WHO) launched an initiative to eliminate viral hepatitis, with the aim of reducing new infections by 90% and deaths by 65% by 2030. Mexico is one of 38 focus countries identified by the WHO, collectively accounting for 80% of global infections and deaths. While hepatitis B and C are commonly diagnosed in Mexico, routine diagnosis for hepatitis D and E is lacking, with no specific epidemiological data available. In 2020, Mexico implemented the National Hepatitis C Elimination Program, focusing on preventing new infections, reducing complications like cirrhosis and hepatocellular carcinoma, ensuring access to treatment, and improving patient care. However, this program has not been extended to hepatitis B and E. Addressing the challenges of viral hepatitis control in Mexico requires increased resource allocation, expanded diagnosis, vaccination for hepatitis A and B, and treatment coverage for hepatitis B and C, along with multisectoral engagement. This work provides an overview of Mexico's response to the global initiative, highlighting its progress, challenges, and areas of opportunity. |
